We conducted a 54-week, open-label, prospective, followup study to evaluate the efficacy and tolerability of etanercept administered at 50 mg once weekly in patients with active AS who were resistant or intolerant to previous therapy with infliximab.
Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study / Cantini, Fabrizio; Niccoli, Laura; Benucci, Maurizio; Chindamo, Daniela; Nannini, Carlotta; Olivieri, Ignazio; Padula, Angela; Salvarani, Carlo. - In: ARTHRITIS AND RHEUMATISM. - ISSN 0004-3591. - 55:(2006), pp. 812-816. [10.1002/art.22236]
Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study
SALVARANI, CARLO
2006
Abstract
We conducted a 54-week, open-label, prospective, followup study to evaluate the efficacy and tolerability of etanercept administered at 50 mg once weekly in patients with active AS who were resistant or intolerant to previous therapy with infliximab.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
